产品介绍 评论(0)
物种
Human分子别名
LR3 Insulin-like Growth Factor-I, MGF, IGFI, IGF1A, IGF, IBP1Accession
P05019表达序列
Gly49-Ala118 (Glu51Arg)
表达宿主
E.coli分子量
10 kDa (Reducing)
纯度
>95% by SDS-PAGE.内毒素含量
<0.1EU/μg活性
EC50 = 0.87-2.0 ng/mL标记
Unconjugated标签
No Tag性状
Lyophilized Powder缓冲体系
50mM HAc
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.文献引用
Endocrinology. 1999 Oct;140(10):4699-705.
J Neurotrauma. 2018 Jul 1;35(13):1467-1480.
IGF-I is a well-characterized basic peptide secreted by the liver that circulates in the blood. It has growth-regulating, insulin-like, mitogenic activities. IGF-I is a growth factor that has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to IGF-II, which is also a major fetal growth factor. Human Long R3 Insulin-like Growth Factor-I (rhLR3-IGF-I) contains an 83 amino acid analog of human IGF-I. Compared to the complete human IGF-I sequence, an addition of the rhLR3-IGF-1 includes the substitution of an Arg for the Glu at position 3 (hence R3) and a13 amino acid extension peptide at the N-terminus. An enhanced potency is due to the markedly decreased binding of human Long R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs.
生物活性
Measured in a serum-free cell proliferation assay using human MCF-7 cells. The EC50 for this effect is 0.87-2.0 ng/mL.
电泳
2μg (R: reducing condition, N: non-reducing condition).







评论(0)